32 Results

Cincinnati Edition: COVID 'long haulers' face symptoms months...

January 4, 2021

Richard Becker, MD, director of the UC Heart, Lung and Vascular Institute, spoke with WVXU for a segment about his interaction with former COVID patients who are still battling health ailments related to fighting off the pandemic. Becker said worldwide there are 80 million known cases of COVID-19 and 1.7 million who died as a result. That means more than 78 million people have survived infection including 600,000 in the state of Ohio.

UC researchers tackle cardiomyopathy in the lab

November 14, 2020

Two investigators in the University of Cincinnati College of Medicine present their research findings at the 2020 American Heart Association Virtual Scientific Sessions. Brittany Duncan, a doctoral student in molecular, cellular and biochemical pharmacology, is testing an investigational drug’s impact on diabetic cardiomyopathy in animal models. Her colleague, Sholeh Bazrafshan, MD, a visiting scholar, is examining the impact exercise-related stress can have on individuals who carry a genetic variant of a heart protein linked to hypertrophic cardiomyopathy, commonly known as an enlarged heart.

Contagion Live: Targeting Lung Blood Vessel Inflammation in...

September 30, 2020

Richard Becker, MD, director of the UC Heart, Lung and Vascular Institute, was interviewed by a reporter for Contagion Live about a new phase 2 clinical trial UC and UC Health are conducting using the drug razuprotafib, to lessen inflammation of the blood vessels in COVID-19 patients. Razuprotafib activates a key pathway for stabilizing blood vessels in the lungs and may prevent or treat respiratory distress in COVID-19 patients.

UC researchers to study drug’s effects on COVID-19 patients

September 22, 2020

Researchers at the University of Cincinnati and UC Health will host a Phase 2 clinical trial (NCT04511650) to examine the effects of a drug that targets blood vessel inflammation and injury in patients with COVID-19. They will study the effects of razuprotafib, an investigational drug that activates a key pathway for stabilizing blood vessels in the lung and other organs in patients with moderate to severe cases of the respiratory illness caused by the novel coronavirus SARS-CoV-2. The drug may prevent and treat respiratory distress in COVID-19 patients. The Phase 2 clinical trial will assess safety, tolerability and efficacy of razuprotafib.

Yahoo News: Five Black UC faculty members receive National...

September 8, 2020

Five African-American researchers and healthcare professionals on UC’s medical campus have received sizable grants from the National Institutes of Health during the past 18 months. The faculty members were interviewed by WCPO to help showcase innovation and the diverse voices and perspectives they bring as the healthcare community attempts to ease health disparities in communities of color in Cincinnati and beyond.

Load More
Debug Query for this